Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study.
Adolescent
Adult
Aged
Anti-Bacterial Agents
/ adverse effects
Azabicyclo Compounds
/ adverse effects
Bacterial Proteins
/ biosynthesis
Ceftazidime
/ adverse effects
Child
Child, Preschool
Colistin
/ adverse effects
Disease Outbreaks
Drug Combinations
Female
Gentamicins
/ adverse effects
Humans
Infant
Infant, Newborn
Italy
/ epidemiology
Klebsiella Infections
/ drug therapy
Klebsiella pneumoniae
/ enzymology
Male
Meropenem
/ adverse effects
Middle Aged
Pharmacovigilance
Tigecycline
/ adverse effects
United Kingdom
/ epidemiology
Young Adult
beta-Lactamases
/ biosynthesis
Adverse drug reactions
Ceftazidime/avibactam
Colistin
Gentamicin
KPC outbreak
Meropenem
Tigecycline
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
12 11 2019
12 11 2019
Historique:
received:
05
08
2019
accepted:
21
10
2019
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
31
3
2020
Statut:
epublish
Résumé
The management of Klebsiella pneumoniae carbapenemase producing (KPC) infections represents a major challenge. Several safety and efficacy concerns are shared by available antibiotics used in KPC infections, leading to the occurrence of serious adverse drug reactions (ADRs), with ceftazidime-avibactam possibly showing a more favourable risk-benefit profile. We investigated the potential impact of resistance on ADR reports in countries with different prevalence of KPC isolates (Italy vs. United Kingdom [UK]), and described safety profile of newer and older antibiotics used in KPC infections. Three spontaneous reporting systems (SRSs) with different features (Italy, UK and worldwide FAERS) were used to describe safety profiles of colistin, meropenem, tigecycline, gentamicin and ceftazidime-avibactam in terms of System Organ Class and Preferred Term level. ADRs were plotted with prevalence of KPC isolates in Italy and UK. A comparison between before-after the KPC outbreak period (1999-2008 vs. 2009-2018) of overall and serious ADRs for selected antibiotics in each SRS was performed. Relationship between total and serious number of ADR reports per year and KPC isolates per year after KPC outbreak (2009-2017) was investigated for both Italy and UK. A total of 16,329 ADR reports were collected in the three SRSs, with meropenem (42.6%) and gentamicin (36.9%) having the highest number of reports. Significant increase in total and serious ADR reports after the KPC outbreak compared to previous 10 years was found for colistin, meropenem and gentamicin (p < 0.01). No significant increase in tigecycline ADRs was reported in FAERS and UK database. Unexpected safety signals involving selected antibiotics were not detected. Significant positive relationship between overall and serious ADR reports and KPC isolates per year for both Italy (p < 0.01; p = 0.005) and UK (p = 0.032; p = 0.013) was found. KPC outbreak led to significant increase in ADRs to selected antibiotics, and a close relationship with antimicrobial resistance was found, both in countries with high and low resistance rate. New safety signals were not detected for selected agents. Active surveillance should be maintained to promptly identify unexpected safety issues.
Sections du résumé
BACKGROUND
The management of Klebsiella pneumoniae carbapenemase producing (KPC) infections represents a major challenge. Several safety and efficacy concerns are shared by available antibiotics used in KPC infections, leading to the occurrence of serious adverse drug reactions (ADRs), with ceftazidime-avibactam possibly showing a more favourable risk-benefit profile. We investigated the potential impact of resistance on ADR reports in countries with different prevalence of KPC isolates (Italy vs. United Kingdom [UK]), and described safety profile of newer and older antibiotics used in KPC infections.
METHODS
Three spontaneous reporting systems (SRSs) with different features (Italy, UK and worldwide FAERS) were used to describe safety profiles of colistin, meropenem, tigecycline, gentamicin and ceftazidime-avibactam in terms of System Organ Class and Preferred Term level. ADRs were plotted with prevalence of KPC isolates in Italy and UK. A comparison between before-after the KPC outbreak period (1999-2008 vs. 2009-2018) of overall and serious ADRs for selected antibiotics in each SRS was performed. Relationship between total and serious number of ADR reports per year and KPC isolates per year after KPC outbreak (2009-2017) was investigated for both Italy and UK.
RESULTS
A total of 16,329 ADR reports were collected in the three SRSs, with meropenem (42.6%) and gentamicin (36.9%) having the highest number of reports. Significant increase in total and serious ADR reports after the KPC outbreak compared to previous 10 years was found for colistin, meropenem and gentamicin (p < 0.01). No significant increase in tigecycline ADRs was reported in FAERS and UK database. Unexpected safety signals involving selected antibiotics were not detected. Significant positive relationship between overall and serious ADR reports and KPC isolates per year for both Italy (p < 0.01; p = 0.005) and UK (p = 0.032; p = 0.013) was found.
CONCLUSION
KPC outbreak led to significant increase in ADRs to selected antibiotics, and a close relationship with antimicrobial resistance was found, both in countries with high and low resistance rate. New safety signals were not detected for selected agents. Active surveillance should be maintained to promptly identify unexpected safety issues.
Identifiants
pubmed: 31718688
doi: 10.1186/s40360-019-0364-0
pii: 10.1186/s40360-019-0364-0
pmc: PMC6852729
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azabicyclo Compounds
0
Bacterial Proteins
0
Drug Combinations
0
Gentamicins
0
avibactam, ceftazidime drug combination
0
Tigecycline
70JE2N95KR
Ceftazidime
9M416Z9QNR
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Meropenem
FV9J3JU8B1
Colistin
Z67X93HJG1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
65Références
Clin Microbiol Rev. 2018 Feb 14;31(2):
pubmed: 29444952
JAMA. 2019 Jan 15;321(2):188-199
pubmed: 30644987
Expert Rev Anti Infect Ther. 2014 Apr;12(4):397-400
pubmed: 24597542
Clin Microbiol Infect. 2018 Feb;24(2):133-144
pubmed: 28893689
J Intern Med. 2015 May;277(5):501-12
pubmed: 25556628
Front Microbiol. 2016 Jun 13;7:895
pubmed: 27379038
Lancet Infect Dis. 2009 Apr;9(4):228-36
pubmed: 19324295
Expert Opin Drug Saf. 2012 May;11(3):381-99
pubmed: 22220627
Diagn Microbiol Infect Dis. 2019 May;94(1):41-49
pubmed: 30635223
Virulence. 2017 May 19;8(4):403-416
pubmed: 27384881
Clin Infect Dis. 2019 Jan 18;68(3):355-364
pubmed: 29893802
MMWR Morb Mortal Wkly Rep. 2016 Mar 11;65(9):235-41
pubmed: 26963489
Curr Opin Infect Dis. 2012 Dec;25(6):626-33
pubmed: 23041772
J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii3-4
pubmed: 23772044
Br J Clin Pharmacol. 2018 Feb;84(2):223-238
pubmed: 28940715
Curr Opin Infect Dis. 2018 Dec;31(6):566-577
pubmed: 30379732
Pharmacotherapy. 2013 Jan;33(1):63-8
pubmed: 23307547
Nutr Metab Cardiovasc Dis. 2018 Jun;28(6):533-542
pubmed: 29625780
Biol Pharm Bull. 2012;35(6):967-70
pubmed: 22687540
Antimicrob Agents Chemother. 2001 Apr;45(4):1151-61
pubmed: 11257029
Clin Infect Dis. 2018 Jan 6;66(2):163-171
pubmed: 29020404
New Microbiol. 2015 Apr;38(2):121-36
pubmed: 25915055
Drugs. 2003;63(14):1511-24
pubmed: 12834367
Target Oncol. 2019 Apr;14(2):205-221
pubmed: 30927173
Open Forum Infect Dis. 2018 Jun 28;5(7):ofy150
pubmed: 30046639
Emerg Infect Dis. 2014 Jul;20(7):1170-5
pubmed: 24959688
Drugs Real World Outcomes. 2018 Jun;5(2):91-99
pubmed: 29476420
Drug Saf. 2016 Jan;39(1):59-68
pubmed: 26446144
Drug Saf. 2007;30(8):657-68
pubmed: 17696578
Clin Microbiol Infect. 2012 May;18(5):413-31
pubmed: 22507109